| [1] |
Gniadek TJ, Arndt PA, Leger RM, et al. Drug-induced immune hemolytic anemia associated with anti-vancomycin complicated by a paraben antibody[J].Transfusion, 2018, 58(1):181-188.
|
| [2] |
Smaga I, Fierro D, Mesa J, et al. Molecular changes evoked by the beta-lactam antibiotic ceftriaxone across rodent models of substance use disorder and neurological disease[J]. NeurosciBiobehav Rev, 2020, 115: 116-130. doi: 10.1016/j.neubiorev.2020.05.016.
|
| [3] |
Renard D, Rosselet A. Drug-induced hemolytic anemia: pharmacological aspects[J]. TransfusClinBiol, 2017, 24(3): 110-114.
|
| [4] |
Leicht HB, Weinig E, Mayer B, et al. Ceftriaxone-induced hemolytic anemia with severe renal failure: a case report and review of literature[J]. BMC PharmacolToxicol, 2018, 19(1): 67.
|
| [5] |
Nguyen TN, Fihman V, Maenulein E, et al. Drug-induced immune hemolytic anemia investigation: Comparison between tube test and microcolumn agglutination(gel test)for the detection of drug-dependent antibodies in the presence of soluble drug[J]. TransfusClinBiol, 2020, 27(3):133-138.
|
| [6] |
Pecker LH, TimsarA, Pary PP, et al. Unusual serological findings associated with ceftriaxone-induced immune hemolytic anemia in a child with disseminated low-grade glioma[J]. PediatrBlood Cancer, 2016, 63(10): 1852-1855.
|
| [7] |
Renard D, Rosselet A. Drug-induced hemolytic anemia: Pharmacological aspects[J]. TransfusClinBiol, 2017, 24(3):110-114.
|
| [8] |
Quillen K, Lane C, Hu E, et al. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection[J]. Pediatr Infect Dis J, 2008, 27(4): 357-358.
|
| [9] |
Van Buren NL, Gorlin JB, Reed RC, et al. Ceftriaxone-induced drug reaction mimicking acute splenic sequestration crisis in a child with hemoglobin SC disease[J]. Transfusion, 2018, 58(4):879-883.
|
| [10] |
Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007[J]. Immunohematology, 2014, 30(2): 66-79.
|
| [11] |
Mayer B, Bartolmäs T, Yürek S, et al. Variability of findings in drug-induced immune haemolyticanaemia: experience over 20 years in a single center[J]. TransfusMed Hemother, 2015, 42(5): 333-339.
|
| [12] |
Singh A, Singhania N, Sharma A, et al. Ceftriaxone-Induced Immune Hemolytic Anemia[J]. Cureus, 2020, 12(6):e8660.
|
| [13] |
Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia[J]. Transfusion, 2012, 52(3): 602-612.
|
| [14] |
Northrop MS, Agarwal HS. Ceftriaxone-induced hemolytic anemia: case report and review of literature[J]. J Pediatr Hematol Oncol, 2015, 37(1): e63-66.
|
| [15] |
谢婷婷,余自华. 依库珠单抗在儿童非典型溶血尿毒综合征中的应用[J]. 中华实用儿科临床杂志, 2018, 33(17): 1351-1353. XIE Tingting, YU Zihua. Application of Eculizumab in children with atypical hemolytic uremic syndrome[J].Chinese Journal of Applied Clinical Pediatrics, 2018, 33(17): 1351-1353.
|
| [16] |
Kim Ma, Stephen Caplan. Refractory IgG warm autoimmune hemolytic anemia treated with eculizumab: a novel application of anticomplement therapy[J]. Case Rep Hematol, 2016, 2016: 9181698. doi: 10.1155/2016/9181698.
|
